ArticleBrain and behavior2017
Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.
Article in Brain and behavior, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Rebound effect, discontinuation, and withdrawal syndromes associated with drugs used in psychiatric and neurological disorders.Pharmacological reports : PR · 2025Review
- Integrinβ-1 in disorders and cancers: molecular mechanisms and therapeutic targets.Cell communication and signaling : CCS · 2024Review
- Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.Therapeutic advances in neurological disorders · 2024Article
- Article
- Natalizumab treatment during pregnancy in multiple sclerosis-clinical and bioethical aspects of an ongoing debate.Wiener medizinische Wochenschrift (1946) · 2022Article
- Integrins regulate stemness in solid tumor: an emerging therapeutic target.Journal of hematology & oncology · 2021Review
- Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review.Biologics : targets & therapy · 2021Review
- Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2020Article
- COVID-19 and MS disease-modifying therapies.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.Therapeutics and clinical risk management · 2020Review
- Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020Observational
- Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring.Frontiers in immunology · 2020Review
- Multiple sclerosis.The mental health clinician · 2019Article
- An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion.Neurology and therapy · 2019Article
- Dependence, withdrawal and rebound of CNS drugs: an update and regulatory considerations for new drugs development.Brain communications · 2019Review
- Rituximab before and during pregnancy: A systematic review, and a case series in MS and NMOSD.Neurology(R) neuroimmunology & neuroinflammation · 2018Article
- Cladribine tablets' potential role as a key example of selective immune reconstitution therapy in multiple sclerosis.Degenerative neurological and neuromuscular disease · 2018Review
- Integrins as Therapeutic Targets: Successes and Cancers.Cancers · 2017Review
- Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.Brain and behavior · 2017Article
- Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNatalizumab (NTZ) is an effective drug for the treatment of relapsing-remitting multiple sclerosis. In some patients discontinuation is mandatory due to the risk of progressive multifocal leukoencephalopathy. However, severe clinical and radiological worsening has been described after drug cessation. Our aim was to describe the clinical and radiological features of the rebound phenomenon. MATERIAL AND
methodsPatients switched from NTZ to Fingolimod (FTY) who had presented a rebound after discontinuation were selected. Clinical and magnetic resonance imaging (MRI) data were collected.
resultsFour JC virus positive patients were included. The mean disease duration was 9.5 years (
conclusionDiscontinuation of NTZ treatment may trigger a severe rebound with marked clinical and radiological worsening. A very careful evaluation of benefit-risk should be considered before NTZ withdrawal, and a close monitoring and a short washout period is recommended after drug withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.